Loading
Genetic and Kidney Cyst Diseases / Genomics and Rare Diseases · Journal article
The Journal of Clinical Endocrinology & Metabolism · August 14, 2026
A consensus or society position rather than new primary data.
This is a European expert consensus statement recommending structured, coordinated care through designated centres of expertise for patients with monogenic obesity who may be eligible for newly approved MC4R agonist therapies. The statement emphasizes the need for early diagnosis, equitable access, continuous treatment monitoring, and provision of care by trained professionals, while acknowledging limited long-term safety and efficacy data in these ultra-rare populations (fewer than 1 in 20,000 to fewer than 1 in 1,000,000).
Journal article. Patients with rare monogenic obesity forms (POMC, PCSK1, LEPR deficiencies and Bardet-Biedl syndrome) eligible for MC4R agonist therapy in Europe.. Intervention: Designation of centres of expertise and structured care protocols for diagnosis and treatment of monogenic obesity, including access to MC4R agonist therapies.. Europe.
MC4R agonists approved for treatment of hyperphagia and obesity in POMC, PCSK1, and LEPR deficiencies and Bardet-Biedl syndrome Affected populations are extremely rare: fewer than 1 in 20,000 (BBS) to fewer than 1 in 1,000,000 individuals Consensus recommends four key goals: early and precise diagnosis, access to therapy for eligible patients, continuous evaluation of treatment response with option for discontinuation without measurable clinical benefit, and care by trained professionals
Source does not report efficacy or safety data for MC4R agonists; only cites regulatory approval. Source does not provide evidence on which to base specific monitoring protocols or discontinuation criteria.
Clinicians should recognize this consensus recommendation as a framework for structuring diagnosis, access, and monitoring of newly approved MC4R agonists in ultra-rare monogenic obesity. Implementation through centres of expertise is advised to optimize resource use and ensure safe, continuous evaluation of treatment efficacy given the lack of long-term outcome data.
European expert consensus recommendation for structured care and centres of expertise in rare monogenic obesity, addressing diagnosis, access, and monitoring for newly approved MC4R agonist therapies.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize this consensus recommendation as a framework for structuring diagnosis, access, and monitoring of newly approved MC4R agonists in ultra-rare monogenic obesity. Implementation through centres of expertise is advised to optimize resource use and ensure safe, continuous evaluation of treatment efficacy given the lack of long-term outcome data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Advances in research enable precision medicine for rare metabolic diseases. The approval of therapies as melanocortin-4 receptor (MC4R) agonists for the treatment of hyperphagia and obesity in monogenic disorders (POMC, PCSK1, and LEPR deficiencies) and Bardet-Biedl syndrome (BBS), affecting fewer than 1 in 20,000 (BBS) to fewer than 1 in 1,000,000 individuals, represents a major advance. These therapies have transformative potential but introduce new responsibilities due to limited patient numbers and lack of long-term data. Equitable access to diagnosis and treatment, expert care and structured monitoring systems facilitate efficient use of resources and can address gaps in knowledge. This article outlines a European expert consensus recommending the designation of centers of expertise to coordinate the diagnosis and treatment of patients with monogenic obesity. The need for structured care protocols based on continued analysis of real-world databases to optimize therapy in a responsible manner is emphasized. The goals are (1) early and precise diagnosis; (2) access for eligible patients to therapy; (3) continuous evaluation of treatment response allowing discontinuation without no measurable clinical benefit and (4) provision of clinical care by trained and experienced professionals.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.